Filtered By:
Source: Cancer Research
Cancer: Lung Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 89 results found since Jan 2013.
Abstract A30: Characterizing the non-linear dependency of the CDK5-Rb axis in non-small cell lung cancer
In spite of recent therapeutics advances and early detection, lung cancer is still the leading cause of cancer-associated deaths worldwide. The five-year survival rates for its two major subtypes, small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are estimated to be 6% and 18%, respectively. This high mortality is due to its aggressive nature even when detected at an early stage. Besides its aggressive nature and tendency for early metastasis, another feature of lung cancer is the inactivation of the retinoblastoma protein (Rb) that is observed in both lung cancer subtypes. NSCLC exhibits Rb inactivation...
Source: Cancer Research - January 15, 2017 Category: Cancer & Oncology Authors: Jaileene Perez-Morales, Mauricio Cabrera-Rios, Jonathan Gonzalez-Flores, Pedro Santiago-Cardona Tags: Systems Biology Source Type: research
Abstract B05: WHSC1L1 and estrogen-independent activation of estrogen receptor-alpha (ER{alpha}) in 8p11 amplicon-bearing cell lines
The 8p11-p12 genomic region is amplified in 15% of breast cancers and 21% of lung squamous cell carcinomas (LSCC) and is associated with poorer prognosis. This genomic region harbors several oncogenes, three of which are epigenetic modifiers of chromatin (WHSC1L1, KAT6A, ASH2L). WHSC1L1 is a histone methyltransferase (HMT) that is expressed in 2 isoforms. The long isoform (WH-long) encompasses the entire coding region and is associated with dimethylation of lysine 36 on histone 3 (H3K36me2) to facilitate transcriptional elongation. The short isoform (WH-short) is produced by alternative splicing at exon 10, resulting in a ...
Source: Cancer Research - January 14, 2016 Category: Cancer & Oncology Authors: Mills, J. N., Irish, J., Turner-Ivey, B., Ethier, S. P. Tags: Cancer Genomics and Epigenomics Source Type: research
Abstract A2-18: The challenges of using large-scale genomics data to identify novel drivers of lung cancer
Lung cancer is one of the major causes of cancer deaths worldwide and only 30% of patients survive the disease for at least one year after diagnosis. Patients are often too frail to receive systemic chemotherapy and there is an urgent need for less toxic, efficacious, targeted therapies. Despite recent efforts with large-scale genomics data we still lack knowledge about driver mutations for the majority of lung cancers.Increasingly, cancer researchers are using online cancer genomic databases to identify novel targets to investigate. A comparison of two prominent databases from different institutes (CCLE and COSMIC) reveal...
Source: Cancer Research - November 15, 2015 Category: Cancer & Oncology Authors: Hudson, A. M., Yates, T., Wirth, C., Li, Y., Trotter, W., Fawdar, S., Miller, C., Brognard, J. Tags: Genomics and Target Discovery Source Type: research
Abstract 29: Potent curcumin analog FLLL12 induces apoptosis in lung cancer cells through death receptor-5-dependent pathway
Conclusions: Our results strongly suggest that FLLL12 induces apoptosis of lung cancer cell lines by posttranscriptional regulation of DR5 through activation of protein tyrosine phosphatase(s). This study was supported by NCI R03 CA171663, NCI P50 CA128613 and Robbins Scholar Award of Winship Cancer Institute of Emory University.Citation Format: Abedul Haque, Mohammad A. Rahman, James R. Fuchs, Zhuo G. Chen, Fadlo R. Khuri, Dong M. Shin, A.R.M. Ruhul Amin. Potent curcumin analog FLLL12 induces apoptosis in lung cancer cells through death receptor-5-dependent pathway. [abstract]. In: Proceedings of the 106th Annual Meeting ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Haque, A., Rahman, M. A., Fuchs, J. R., Chen, Z. G., Khuri, F. R., Shin, D. M., Amin, A. R. M. R. Tags: Molecular and Cellular Biology Source Type: research
Abstract LB-247: Querying the RAS genomic network with siRNAs and and flow cytometry: Automatic, multidimensional phenotyping of 135 cancer cell lines by Gaussian mixture fitting and expectation maximization
To discover novel therapeutic modalities and genomic predictors of response, large screen utilizing small molecules or sh/siRNA are performed on increasingly large collections of cancer cell lines. However these screens suffer from two main limitations: 1) the off-target effects of the probes 2) the coarse measurement of the cellular response that cannot distinguish between different outcomes such as proliferation block and apoptosis.Here we profile 50 lung cancer cell lines using highly specific combinations of siRNAs against effector nodes of KRAS, and measured several characteristics of phenotypic response by flow cytom...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Amzallag, A., Yuan, T. L., Bagni, R., Yi, M., Stephens, R., Ramawamy, S., McCormick, F., Benes, C. H. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 54: Ezrin enhances signaling and nuclear translocation of the epidermal growth factor receptor in non-small cell lung cancer cells
The cytoskeletal cross linker protein ezrin is a member of the ezrin-radixin-moesin (ERM) family and plays important roles not only in cell motility, cell adhesion, and apoptosis, but also in various cell-signaling pathways. Ezrin interacts with EGFR in the cell membrane and involves in cell motility events, but little is known about the effects of this interaction on the EGFR signaling pathway. We investigated the role of Ezrin in EGFR signaling and nuclear trafficking in non-small cell lung cancer (NSCLC) cell lines. The ligand induced interaction between Ezrin and EGFR was evaluated by immunoprecipitation (IP) and immun...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Saygideger Kont, Y., Celik, H., Erkizan, H. V., Minas, T., Han, J., Toretsky, J., Uren, A. Tags: Molecular and Cellular Biology Source Type: research
Abstract 744: Transactivation of HER3 via heterodimerization with epidermal growth factor receptor (EGFR) or insulin-like growth factor 1 receptor (IGF-1R) contributes to adaptive resistance to NVP-BKM120 in non-small cell lung cancer (NSCLC) and squamous cell carcinom
Conclusions: Transactivation of HER3 via EGFR or IGF-1R attenuates the effectiveness of NVP-BKM120 in multiple NSCLC and SCCHN cells. Our results suggest that either targeting HER3 directly or indirectly by inhibiting transactivation partners, such as EGFR or IGF-1R, may be potential therapeutic options to overcome adaptive resistance to NVP-BKM120.Note: This abstract was not presented at the meeting.Citation Format: Miran Yun, Jinyoung Sohn, Byoung Chul Cho. Transactivation of HER3 via heterodimerization with epidermal growth factor receptor (EGFR) or insulin-like growth factor 1 receptor (IGF-1R) contributes to adaptive ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Yun, M., Sohn, J., Cho, B. C. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 746: Activation of EGFR bypass signaling through TGF{alpha} overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells
Conclusion: Activation of EGFR signaling pathway through TGFα overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells.Citation Format: Tetsuo Tani, Hiroyuki Yasuda, Junko Hamamoto, Aoi Kuroda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Ichiro Kawada, Katsuhiko Naoki, Hayashi Yuichiro, Tomoko Betsuyaku, Kenzo Soejima. Activation of EGFR bypass signaling through TGFα overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philade...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Tani, T., Yasuda, H., Hamamoto, J., Kuroda, A., Arai, D., Ishioka, K., Ohgino, K., Kawada, I., Naoki, K., Yuichiro, H., Betsuyaku, T., Soejima, K. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 757: Activation of receptor-interacting serine/threonine protein kinase-2 (RIP2K) via EGFR-mediated CRAF transactivation induces the acquired resistance to Dabrafenib in BRAF V600E mutant non-small cell lung cancer
Discussion: Taken together, these findings suggest that the acquired resistance to Dabrafenib in BRAF V600E mutant NSCLC is uniquely mediated by EGFR-RAS-RIPK2-ERK signaling, bypassing MEK1/2, which may necessitate therapeutic strategies different from those of melanoma.Citation Format: Kangwon Jang, Jinyoung Sohn, Sung-Moo Kim, Kyoung Jin Kim, Byoung Chul Cho. Activation of receptor-interacting serine/threonine protein kinase-2 (RIP2K) via EGFR-mediated CRAF transactivation induces the acquired resistance to Dabrafenib in BRAF V600E mutant non-small cell lung cancer. [abstract]. In: Proceedings of the 106th Annual Meeting...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Jang, K., Sohn, J., Kim, S.-M., Kim, K. J., Cho, B. C. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 758: Loss of USP1 translational control as a targetable cisplatin resistance mechanism in non-small cell lung cancer (NSCLC)
Conclusion:Our original approach led to the identification of USP1 as a potential determinant of cisplatin resistance of a lung cancer cell line. USP1 protein levels in tumor samples could potentially serve as a predictive marker of the response to cisplatin. We suggest that small molecule inhibitors of USP1 should be tested as cisplatin-sensitizers. The analysis of the ‘nascent proteome’ by polysome profiling could enable the identification of additional candidates mediating cisplatin-resistance.Citation Format: Carole Helissey, Tony Sourisseau, Hélène Mahieu, Céline Lefebvre, Stephan Vagner, Jean-Charles Soria, Ke...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Helissey, C., Sourisseau, T., Mahieu, H., Lefebvre, C., Vagner, S., Soria, J.-C., Olaussen, K. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 767: Oncogenic mutant KRAS modulates EZH2 expression through MEK-ERK and PI3K/AKT signaling in NSCLC: differential effects of different KRAS mutations and increased efficacy of inhibition combined with EZH2 targeted therapy
Conclusions. Our findings suggest that: 1. oncogenic KRAS G12C and G12D mutations differentially modulate EZH2 expression through MEK-ERK and PI3K/AKT signaling respectively - indicating the need for specific KRAS mutation guided therapy; 2. Inhibition of MEK-ERK and PI3K/AKT in combination with an EZH2 inhibitor should result in a significant increased sensitivity to MEK-ERK and PI3K/AKT targeted therapy in KRAS mutant lung cancers. (Grant support: 5 R01 CA155196 and P50CA70907)Citation Format: Erick M. Riquelme, Li Shen, Jing Wang, Carmen Behrens, George Simon, Vassiliki Papadimitrakopoulou, John D. Minna, Ignacio I. Wis...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Riquelme, E. M., Shen, L., Wang, J., Behrens, C., Simon, G., Papadimitrakopoulou, V., Minna, J. D., Wistuba, I. I. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 519: V-set and immunoglobulin domain containing 1 (VSIG1) demonstrates a tumor suppressive function in gastric cancer and non-small cell lung cancer
V-set and immunoglobulin domain containing 1 (VSIG1) was recently identified as a novel member of immunoglobulin-like cell-adhesion molecules. In human, VSIG1 has 2 transcript variant forms (variant 1 and variant 2). In normal tissues, VSIG1 was reported to be expressed predominantly in stomach and testis. In cancerous tissues, the expression of VSIG1 was shown to be restricted in a part of gastric, esophageal, and ovarian cancers. However, the role of VSIG1 in cancer progression has not been elucidated.VSIG1 protein expression in human normal tissues obtained at autopsy was detected by western blot analysis. We also analy...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Inoue, Y., Kurabe, N., Matsuura, S., Maeda, M., Kahyo, T., Igarashi, H., Funai, K., Niwa, H., Ogawa, H., Shinmura, K., Konno, H., Suda, T., Sugimura, H. Tags: Tumor Biology Source Type: research
Abstract 4: ABT-263 is effective in a subset of non-small cell lung cancer cell lines
Conclusion:We found that Calu3 and BID007 were sensitive to ABT-263. In the sensitive NSCLC cell lines, ABT-263 induces apoptosis irrespective of Mcl-1 expression levels.Citation Format: Aoi Kuroda, Keiko Ohgino, Hiroyuki Yasuda, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Tetsuo Tani, Shigenari Nukaga, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku. ABT-263 is effective in a subset of non-small cell lung cancer cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kuroda, A., Ohgino, K., Yasuda, H., Hamamoto, J., Arai, D., Ishioka, K., Tani, T., Nukaga, S., Kawada, I., Naoki, K., Soejima, K., Betsuyaku, T. Tags: Molecular and Cellular Biology Source Type: research
Abstract 110: The role of the p53 target Wig-1 in senescence and cancer
The wild type p53-induced gene 1, Wig-1 (also known as Zmat3 or PAG608) binds to AU-rich elements in mRNAs and thereby regulates important tumor associated factors including p53, FAS, and N-Myc.Focusing on normal human diploid fibroblasts (HDF), we are now exploring the role of Wig-1 in senescence. SiRNA-mediated Wig-1 depletion increases senescence markers such as Beta-galactosidase staining, H3K9me3, H4K20me3, and p21. Also, Wig-1 is spontaneously downregulated in cells undergoing replicative senescence.The trimethylation of lysine 9 on histone 3 (H3K9me3) is an established marker of cellular senescence and increases upo...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Jerhammar, F., Bersani, C., Djureinovic, D., Micke, P., Wiman, K. G. Tags: Molecular and Cellular Biology Source Type: research
Abstract LB-024: Inhibition of bone morphogenetic protein (BMP) type I receptors in lung cancer cells activates the TGF{beta} signaling cascades which increases Id1 expression by TAK1
This study reveals that TGFβ signaling can increase the expression of Id1 when BMP signaling is inhibited in lung cancer cells, which is mediated by TAK1. The data suggests that the inhibition of both the BMP and TGF signaling pathways enhances growth suppression of lung cancer cells that involves the downregulation of Id1.Citation Format: John E. Langenfeld, Elaine Langenfeld, Monica Castle. Inhibition of bone morphogenetic protein (BMP) type I receptors in lung cancer cells activates the TGFβ signaling cascades which increases Id1 expression by TAK1. [abstract]. In: Proceedings of the 106th Annual Meeting of the Americ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Langenfeld, J. E., Langenfeld, E., Castle, M. Tags: Molecular and Cellular Biology Source Type: research
